RALEIGH, N.C., Nov. 28, 2016 /PRNewswire/ -- Innovate Biopharmaceuticals Inc., a clinical stage biotechnology company with two drug candidates entering clinical trials for the treatment of celiac disease and ulcerative colitis, will make a presentation at the 28 th Annual Piper Jaffray Healthcare Conference in New York this week. The presentation is scheduled for Tuesday, Nov. 29, at 3 p.m. at the Lotte New York Palace Hotel at 50 th St. and Madison Avenue. Company executives will also meet with interested investors on Nov. 29-30. Investors can email the company to schedule one-on-one meetings on Nov. 29: firstname.lastname@example.org. About Innovate Biopharmaceuticals Inc.Innovate is a privately held, clinical stage biotechnology company focused on developing novel autoimmune/inflammation medicines. Innovate's lead drug candidate, Larazotide acetate (INN-202), is a novel oral peptide that has consistently reduced clinical symptoms of celiac disease in multiple clinical trials testing more than 800 patients. Larazotide has completed a large phase 2b study and will start Phase 3 trials in 2017. Larazotide's unique mechanism of action of reducing antigen trafficking across epithelial cells makes it a promising therapeutic for multiple diseases involving "leaky tight junctions." Innovate's second therapeutic in clinical development, INN-108, is an oral small molecule entering Phase 2 trials for the treatment of adult orphan ulcerative colitis as well as mild to moderate ulcerative colitis. INN-108 is a prodrug that only becomes activated in the colon. The convenience of a liquid formulation will be important to children and the aging.